Adjuvant and neoadjuvant approaches in gastric cancer

Cancer Journal

Volumn 13, Issue 3, 2007, Pages 168-174

  Ng, Kimmie ^a   Meyerhardt, Jeffrey A ^a   Fuchs, Charles S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

Adenocarcinoma; Adjuvant; Chemotherapy; Combined modality therapy; Local; Neoadjuvant therapy; Neoplasm recurrence; Neoplasm staging; Radiotherapy; Stomach neoplasms radiotherapy; Stomach neoplasms drug therapy; Stomach neoplasms mortality

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN C; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LEUKEMIA; MULTIPLE CYCLE TREATMENT; NORTH AMERICA; PATIENT CARE; POPULATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34848841265     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318074e351     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Blanke CD, Corless CL, Schwarz RE, et al. Gastric Cancer. 9th ed. Lawrence, KS: CMP Healthcare Media; 2005.
3. Hazard L, O'Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol. 2006;12:1511-1520.
4. Chadha MK, Kuvshinoff BW, Javle MM. Neoadjuvant therapy for gastric cancer. Oncology (Williston Park). 2005;19:1219-1227; discussion 27-28, 31-32.
5. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000; 88:921-932.
6. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333:32-41.
7. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 1994;343:1309-1312.
8. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg. 1977;2: 213-221.
9. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995;13:2757-2763.
10. Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer: a combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17:262-269.
11. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441-1447.
12. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35:1059-1064.
13. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837-843.
14. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21-27.
15. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608.
16. Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gas-trectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002;9:394-400.
17. Marrelli D, Roviello F, de Manzoni G, et al. Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study. World J Surg. 2002;26:1160-1165.
18. Gunderson LL. Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol. 2002;12:150-161.
19. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
20. Macdonald JS Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival and overall survival in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). Paper presented at: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA.
21. Kelsen DP. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol. 2000;18(21 suppl):32S-34S.
22. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev. 2000;26:243-255.
23. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg. 1993;218:583-592.
24. Hundahl SA, Menck HR, Mansour EG, et al. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997;80:2333-2341.
25. Fuchs C, Tepper JE, Niedwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional 5-FU (ECF) before and after CI 5-FU and radiotherapy: Interim toxicity results from Intergroup trial CALGB 80101. Paper presented at: 2006 Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA.
26. Lim L, Michael M, Mann GB, et al. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220-6232.
27. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42:929-934.
28. Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol. 2002;80:72-78.
29. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer. 1996;74:1651-1654.
30. Lowy AM, Mansfield PF, Leach SD, et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303-308.
31. Fink U, Schuhmacher C, Stein HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg. 1995;82:1248-1252.
32. Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg. 6:212-223, 2002; discussion 23.
33. Cascinu S, Scartozzi M, Labianca R, et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 2004;90:1521-1525.
34. Barone C, Cassano A, Pozzo C, et al. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology. 2004;67:48-53.
35. Persiani R, D'Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 89:227-236, 2005; discussion 37-38.
36. Songun I, Keizer HJ, Hermans J, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 1999;35:558-562.
37. Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643-649.
38. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
39. Cunningham D, Rao S, Starling N, et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer: the REAL-2 trial. J Clin Oncol. 2006;24(18 suppl):LBA4017.
40. Phase III randomized study of preoperative versus postoperative chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with locally advanced operable gastric carcinoma. Available at: http://www. cancer.gov/clinicaltrials/SWS-SAKK-43/99 Accessed: January 24, 2007.
41. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-2780.
42. Okawara GS WK, Donohue JH, et al. A phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adeno-carcinoma of the stomach (RTOG 99-04). J Clin Oncol. 2005;23(16 suppl):4019.
43. Bouche O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488-1497.
44. Tepper JE, Krasna M, Niedzwiecki D, et al. Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781. J Clin Oncol. 2006;24(18 suppl):4012.